Celcuity, Inc.

CELC Healthcare Biotechnology

EPS
−38.5%
Free cash flow
−53.3%
Total debt
+658.7%

Quarter to June 2026, against a year earlier

66.82 2.78 +4.34%
Market cap
$3.1B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
10.55 7.71 13.43 25.46 34.06 10.26 21.12 38.08 42.35 13.27
Net Debt/EBITDA
0.71 1.23 2.18 3.44 2.51 1.27 2.51 3.23 4.15 1.81
Debt/Equity
3.20 0.85 0.27 0.26 0.21 0.00 0.00 0.00 0.00 0.00
ROE
(163.80%) (87.54%) (46.63%) (39.88%) (73.63%) (61.12%) (32.97%) (26.37%) (33.79%) (62.30%)
ROA
(49.75%) (51.23%) (34.76%) (30.86%) (59.89%) (57.01%) (31.78%) (25.80%) (32.88%) (58.30%)
ROIC
0.00% 0.00% 0.00% (14,733.36%) 0.00% (8,215.44%) (845.90%) (1,050.38%) (52.07%) 0.00%
Return on Tangible Assets
(41.95%) (52.43%) (36.11%) (23.95%) (35.60%) (82.09%) (38.38%) (29.49%) (25.85%) (58.99%)
Average Days of Receivables
— — — 0.00 0.00 0.00 0.00 — — —
Free Cash Flow per Share
(3.28) (2.12) (2.28) (2.35) (1.52) (0.70) (0.62) (0.66) (0.70) (0.46)
Book value per Share
2.15 2.93 5.90 8.68 5.13 1.14 1.89 2.50 4.21 0.89
Free Cash Flow
(153.53) (83.72) (53.91) (36.17) (20.39) (7.24) (6.38) (6.70) (5.19) (2.93)
Other line items

Show all line items

Columns are period end dates